Home › Burkitt Lymphoma › Iowa › Des Moines
Burkitt Lymphoma clinical trials in Des Moines, IA
4 studies for Burkitt Lymphoma are looking for participants at sites in and around Des Moines (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- Blank Children's Hospital, Des Moines
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecruitingPhase 2
- Blank Children's Hospital, Des Moines
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- Blank Children's Hospital, Des Moines
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- Blank Children's Hospital, Des Moines
Burkitt Lymphoma trials in other cities
- Houston, TX21 studies
- Milwaukee, WI16 studies
- Philadelphia, PA16 studies
- New York City, NY14 studies
- Chicago, IL13 studies
- Seattle, WA12 studies
- Cincinnati, OH12 studies
- Atlanta, GA11 studies
- Boston, MA10 studies
- Los Angeles, CA10 studies
- Durham, NC10 studies
- Aurora, CO10 studies
Other studies in Des Moines
- Non-Small Cell Lung Cancer11 studies
- Lung Cancer10 studies
- Breast Cancer8 studies
- Chronic Lymphocytic Leukemia8 studies
- Colorectal Cancer7 studies
- Bladder Cancer6 studies
- Overweight6 studies
- Cardiovascular Disease5 studies
- Multiple Myeloma5 studies
- Melanoma5 studies
- Diffuse Large B-Cell Lymphoma5 studies
- Acute Myeloid Leukemia5 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.